The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

On June 30, AbbVie announced its intention to acquire Capstan Therapeutics in a deal valued at up to $2.1 billion in cash.

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...

AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn ...

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...

AbbVie agreed to acquire Capstan Therapeutics, including its lead asset, for $2.1 billion in cash. The North Chicago, Ill., ...

AbbVie announced it will acquire Capstan Therapeutics, a startup developing CAR-T therapies for autoimmune conditions, ...

Capstan brings a new modality to AbbVie’s immunology pipeline. The most advanced Capstan program is CPTX2309, which is being developed as a treatment for B cell-mediated autoimmune disorders.

ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.

On June 30, AbbVie announced its intention to acquire Capstan Therapeutics in a deal valued at up to $2.1 billion in cash. The acquisition will expand AbbVie’s product pipeline, ...

Recently, AbbVie announced its intention to acquire Capstan Therapeutics, a clinical-stage biotechnology firm specializing in in-vivo cell engineering through RNA delivery platforms, for up to $2. ...